Adenoviral targeting of malignant melanoma for fluorescence-guided surgery prevents recurrence in orthotopic nude-mouse models

Malignant melanoma requires precise resection in order to avoid metastatic recurrence. We report here that the telomerase-dependent, green fluorescent protein (GFP)-containing adenovirus OBP-401 could label malignant melanoma with GFP in situ in orthotopic mouse models. OBP-401-based fluorescence-guided surgery (FGS) resulted in the complete resection of malignant melanoma in the orthotopic models, where conventional bright-light surgery (BLS) could not. High-dose administration of OBP-401 enabled FGS without residual cancer cells or recurrence, due to its dual effect of cancer-cell labeling with GFP and killing.

[1]  M. Bouvet,et al.  Eradication of osteosarcoma by fluorescence‐guided surgery with tumor labeling by a killer‐reporter adenovirus , 2016, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[2]  M. Bouvet,et al.  Precise navigation surgery of tumours in the lung in mouse models enabled by in situ fluorescence labelling with a killer-reporter adenovirus , 2015, BMJ Open Respiratory Research.

[3]  M. Bouvet,et al.  Experimental Curative Fluorescence-guided Surgery of Highly Invasive Glioblastoma Multiforme Selectively Labeled With a Killer-reporter Adenovirus. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  M. Bouvet,et al.  Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery , 2015, Cancer Gene Therapy.

[5]  M. Bouvet,et al.  Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma , 2015, Oncotarget.

[6]  A. Slominski,et al.  Melanoma resistance: a bright future for academicians and a challenge for patient advocates. , 2014, Mayo Clinic proceedings.

[7]  Yukihiko Hiroshima,et al.  Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice. , 2014, The Journal of surgical research.

[8]  R. Hoffman,et al.  A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases , 2013, Clinical Cancer Research.

[9]  M. Bouvet,et al.  Tumor-selective, adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection , 2011, Cell cycle.

[10]  Fengzhi Li,et al.  Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture , 2011, Oncotarget.

[11]  P. Choyke,et al.  New strategies for fluorescent probe design in medical diagnostic imaging. , 2010, Chemical reviews.

[12]  N. Senzer,et al.  A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Katsuhiro Hayashi,et al.  In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation , 2009, Proceedings of the National Academy of Sciences.

[14]  S. Kyo,et al.  In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus , 2006, Nature Medicine.

[15]  Meng Yang,et al.  Subcellular imaging in the live mouse , 2006, Nature Protocols.

[16]  K. Yamauchi,et al.  Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. , 2006, Cancer research.

[17]  M. Blagosklonny.  Target for cancer therapy: proliferating cells or stem cells , 2006, Leukemia.

[18]  Robert M. Hoffman,et al.  The multiple uses of fluorescent proteins to visualize cancer in vivo , 2005, Nature Reviews Cancer.

[19]  M. Blagosklonny.  Matching targets for selective cancer therapy. , 2003, Drug discovery today.

[20]  M. Blagosklonny.  Tissue-selective therapy of cancer , 2003, British Journal of Cancer.

[21]  M. Blagosklonny.  Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells , 2001, Leukemia.